Business Wire

MO-VERNE-GLOBAL

15.11.2021 14:02:11 CET | Business Wire | Press release

Share
D9-backed Verne Global Invests $50m to Expand Data Center Campus by 10MW

Verne Global , provider of sustainable data center solutions for high intensity computing, recently acquired by Digital 9 Infrastructure plc (D9), today announced that it is expanding its 40-acre data center campus by a further 10MW of constructed power capacity. The expansion is backed by D9, the investment trust that focuses on sustainable digital infrastructure assets, which will fund the $50m development of new enterprise-class data center space.

Ideally located with access to abundant, low-cost renewable energy and a highly reliable national electrical grid, the Icelandic data center company continues to attract a range of enterprise customers as demand for high intensity compute sees sustained growth across industries. As more companies look to decarbonize their digital infrastructure by powering intensive applications such as artificial intelligence, mathematical modelling and predictive analytics with cleaner, greener energy, Verne Global is expanding now to meet contracted demand. The data center company’s best-in-class onsite technical and operations team will continue to use its specialized expertise to work around the clock to support and optimize the high density environments and workloads it houses.

“We’re seeing sector after sector looking to move into high performance analytics environments and it’s exciting to scale our campus again alongside new and existing customers to meet that need,” said Dominic Ward, CEO at Verne Global. “It’s great to also take this first step into the future as part of the D9 Infrastructure platform, and we are all eagerly looking forward to what comes next.”

“We are proud to support Verne Global and play a part in bringing its vision for the future into reality,” said Thor Johnsen, Head of Digital Infrastructure at Triple Point, D9’s investment manager. “Powered by Iceland’s abundant green power, Verne Global’s expanded data center will be even better placed to provide resilient digital infrastructure that offers a true reduction in carbon emissions for its customers alongside long-term economic and sustainable stability.”

As part of this expansion, Verne Global is partnering with Integra Mission Critical , the modular data center solutions provider, to optimize its delivery of sustainable high intensity compute at scale while fitting out the new data center space. Utilizing Integra’s solution-driven engineering expertise to implement modular data center infrastructure will allow Verne Global to increase sustainability measures in line with its core mission, while promoting scalability and safety, and decreasing cost.

“Verne Global’s facility has been built from the ground up for highly specialist data center services that are sustainable, scalable and bespoke,” said John Kolar, Principal at Integra Mission Critical. “These mutual principles make our companies a natural fit and we’re so excited to be teaming up and putting our decades of experience in solution-driven engineering to good use to provide a quality turnkey infrastructure solution for the new space.”

SC21 delegates can visit Verne Global at the Data Centers by Iceland stand (#1819) at SC21 in St Louis, MO, 15-19 November, 2021.

About Verne Global

Verne Global delivers data center solutions for high intensity computing, engineered for optimal high performance compute and built upon 100% renewable energy. Our clean grid and stable climate cuts costs and energy usage, and our expert team provides on-site, around-the-clock support to maximize performance and flexibility for customer workloads.

Founded in 2012, our Icelandic data center campus powers some of the world’s most innovative and demanding industries, including financial services, earth sciences, life sciences, engineering, scientific research and AI.

About Integra Mission Critical

Integra Mission Critical delivers modular mechanical, electrical and plumbing (MEP) solutions for the mission critical sector. With in-house manufacturing facilities throughout the United States, Europe, and Asia, Integra Mission Critical has a global reach with a local focus. Our solutions-driven engineering enables us to meet each customer’s specific needs across the globe, whether that be specialized cooling for a specific climate, or sustainable solutions for backup power generation.

Integra Mission Critical leverages innovative designs and an integrated approach and combines them with our relentless passion to mitigate risk, compress the schedule, reduce costs, and close the gap between capex and revenue generation.

Founded in 2014, with a focus on cooling solutions, Integra Mission Critical has since expanded into electrical solutions (2017), ranging from electrical skids to modular electrical rooms, to complete modular data centers. Our North America headquarters are in Dallas, Texas with our European headquarters in London, England.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release

Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye